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INTRODUCTION:  Intra-abdominal  desmoid  tumors  (DTs)  are  a  rare and  anatomically  diverse  group  of
locally-aggressive,  benign  neoplasms.  They  are  often  difﬁcult  to  diagnose,  even  in patients  who  possess
risk  factors  for  the  disease.  Even  after  a diagnosis  has  been  reached,  the optimal  therapy  is  often  not
well-deﬁned.
PRESENTATION  OF  CASE:  The  case  discussed  of  a 33-year  old  male  with  a giant  intra-abdominal  desmoid
is an  example  of both  the  diagnostic  and therapeutic  dilemmas  that  arise  when  confronted  with  a  patient
with  a DT.  Initial  confusion  over  diagnosis  led to  ineffective  therapy,  but  once  the  correct  diagnosis  was
made,  the  patient  went  on  to deﬁnitive  surgical  resection.
DISCUSSION:  The differential  diagnosis  of DTs  is broad,  and  the diagnosis  is  often  delayed  due  to nonspe-ase report ciﬁc  presentations.  Immunohistochemistry  is  crucial  in  the  accurate  histological  diagnosis,  which  guides
treatment.  Chemotherapy  and  radiation  have  a role  in  the  management  of  both  primary  and  recurrent
lesions,  but  surgical  resection  remains  the  cornerstone  of treatment.
CONCLUSION:  DTs  present  a clinical  challenge  in  their  diagnosis  and management,  and  despite  providing
standard  medical  and  surgical  treatment,  recurrence  rates  are  high  and  continued  surveillance  is crucial.
©  2016  The  Author(s).  Published  by Elsevier  Ltd on behalf  of  IJS Publishing  Group  Ltd.  This  is  an  open
he CCaccess  article  under  t
. Introduction
Intra-abdominal desmoid tumors (DTs), are benign locally-
ggressive mesenchymal neoplasms that lack the potential for
etastasis. DTs are rare as they account for only 0.03% of all
eoplasms and less than 3% of all soft tissue tumors [1,2]. Approxi-
ately 80% of DTs are sporadic and can occur anywhere in the body,
ut the balance are associated with pregnancy, trauma and genetic
yndromes such as familial adenomatous polyposis (FAP) and are
ore commonly intra-abdominal [3]. In the absence of these risk
actors, intra-abdominal DTs present a diagnostic and therapeutic
ilemma for the surgeon.
We  present the case of a 33-year-old otherwise healthy male
ith a giant intra-abdominal DT that masqueraded as a gastroin-
estinal stromal tumor (GIST) until ultimate diagnosis at the time
f surgical resection.∗ Corresponding author.
E-mail address: adwilliams5@gmail.com (A.D. Williams).
ttp://dx.doi.org/10.1016/j.ijscr.2016.07.044
210-2612/© 2016 The Author(s). Published by Elsevier Ltd on behalf of IJS Publishing 
reativecommons.org/licenses/by-nc-nd/4.0/). BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
2. Case report
A 33-year-old male without medical, surgical or signiﬁcant fam-
ily history presented with a complaint of several months of vague,
diffuse abdominal pain that was  initially attributed to constipation
and treated in the outpatient setting. The patient was  referred to
a surgeon after a computed tomography (CT) scan was  obtained
due to continued symptoms. A large soft tissue mass in the mid
abdomen extending to the upper pelvis was discovered (Fig. 1).
The mass, which consisted of hypodense regions and multiple
vessels, measured 15.7 × 28.6 × 24.2 cm. The mass was displac-
ing bowel loops, but was not causing obstruction or other mass
effect.
In order to inform initial treatment, an ultrasound-guided core
needle biopsy was performed. Histologically, neoplastic spindle
cells were identiﬁed that were moderately positive on immuno-
histochemical staining for muscle speciﬁc actin, S-100 and CD117
and negative for cytokeratin AE1/AE3, desmin and CD34. Cytology
revealed no clonal proliferation of lymphocytes.
Given the patient’s clinical presentation and histopathology,
there was high suspicion that the lesion represented a large GIST.
The patient began neoadjuvant treatment with imatinib. After four
months, the patient’s pain, anorexia and weight loss did not resolve.
A repeat CT scan revealed that the mass had increased signiﬁcantly
Group Ltd. This is an open access article under the CC BY-NC-ND license (http://
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Fig. 1. Computed tomography (CT) scans. At initial presentation (A and B), the soft tissue mass was  15.7 × 28.6 × 24.2 cm.  After a trial of four months of imatinib, the mass
had  grown to a size of 20 × 37 × 32 cm and demonstrated mass effect on surround organs (C and D).
Fig. 2. Gross images. The patient’s abdominal distension improved when compared preoperatively (A) and postoperatively (B). The resection specimen (C) was 45 × 33 × 23 cm,
and  it is pictured here immediately after resection with a 15 cm ruler.
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tig. 3. Histology and immunohistochemistry of resection specimen. Hematoxylin a
f  the appendix on low power (A – 2X, B – 100X). Immunohistochemistry was  posi
o greater than 20 × 37 × 32 cm (Fig. 1) and was causing compres-
ion of the small bowel, ureters, and kidneys.
Due to a progression of the mass on medical therapy, the patient
as taken to the operating room for resection. The patient under-
ent cystoscopy and ureteral stent placement followed by an
xploratory laparotomy. The tumor was found to be tethered to
he omentum and the bowel near the appendix; an omentectomy
nd ileocecectomy were performed in order to remove the tumor
n bloc.
Pathologic analysis of the tumor revealed that it measured
5 × 33 × 23 cm and had a mass of 16.8 kg (Fig. 2). There were
egative resection margins, and with the exception of focal involve-
ent of the appendiceal wall, there was no other involvement of
he bowel. Immunohistochemistry was performed and the mass
as positive for beta-catenin, weakly positive for CD117 and neg-
tive for desmin, smooth muscle actin, CD34, S100 and cytokeratin
Fig. 3). These features are consistent with a diagnosis of desmoid
umor. The patient did well post-operatively and was  discharged
ome one week after surgery. He continues to undergo surveillance
or recurrence.
. Discussion
Intra-abdominal desmoid tumors (DTs) are rare with an inci-
ence of 2-4 cases per million per year [1]. Like the index patient
ho had no family history of colon cancer and no personal history
f abdominal trauma, many intra-abdominal DTs are diagnosed in
symptomatic patients on routine imaging. These lesions tend to be
low-growing and can invade structures without initial symptoms.
s in this case, some patients have vague abdominal complaints
hat are initially dismissed until cross-sectional imaging is per-
ormed and reveals a locally advanced tumor. Because of the lack of
onﬁnement of DTs, other patients present with intestinal obstruc-
ion, organ ischemia and genitourinary complaints depending on
he location into which the tumor has invaded [4,5].in staining of the specimen conﬁrmed a spindle cell morphology and focal invasion
r CD117 (C – 100X) and nuclear -catenin (D – 100X).
This varied location and presentation often results in diagnos-
tic difﬁculty as the differential diagnosis is so broad and includes
more common diseases such as inﬂammatory lesions, liposarcoma,
ﬁbrosarcoma, and GISTs [4]. Histology and immunohistochemistry
on biopsy specimens is helpful in developing a treatment strategy
since these diseases differ greatly in their initial approaches to man-
agement. Relating to this case, both GISTs and DTs are recognizable
in their proliferation of spindle cells [6] and CD117 can be found in
both tumors [7]. Beta-catenin expression, however has been shown
to aide in the distinction since it is found in both the nucleus and
cytoplasm of DT cells but only the cytoplasm of GIST cells.
Both medical and surgical therapies have been trialed for the
treatment of DTs, though large randomized studies are not abun-
dant due to the rarity and relative anatomic diversity of the tumors.
What is clear is that despite the treatment modality, the recur-
rence rate for DTs is 30% to 40% [8]. Watchful waiting has been
advocated for asymptomatic patients with interval cross-sectional
imaging, and has been shown to be equivalent to medical therapy
in progression-free survival [9]. For symptomatic patients, how-
ever, surgery is the mainstay of treatment. Though survival is not
improved by surgical resection, and morbidities such as short gut
syndrome can accompany resection of large or multiple tumors
[3,10], a primary resection with negative margins is the most effec-
tive treatment [11]. Radiation and systemic drug therapy, such as
tamoxifen, doxorubicin, and anti-inﬂammatory drugs, create the
arsenal for medical therapy both in the neoadjuvant setting and
cases of recurrence [1,12].
A high level of clinical suspicion is required in the diagnosis
of desmoid tumors. Surgery has certainly been shown to be an
important treatment modality for DTs regardless of the medical
adjuncts that are used. Close follow up is also essential given the
high recurrence rate despite effective treatment.Conﬂicts of interest
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